Czech National Bank boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 270,216 shares of the biopharmaceutical company's stock after buying an additional 16,598 shares during the period. Czech National Bank's holdings in Gilead Sciences were worth $24,960,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. nVerses Capital LLC purchased a new position in Gilead Sciences during the third quarter valued at $25,000. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Cedar Wealth Management LLC grew its position in shares of Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 160 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the second quarter worth about $33,000. Finally, Quarry LP purchased a new stake in shares of Gilead Sciences in the second quarter worth about $43,000. 83.67% of the stock is owned by institutional investors.
Gilead Sciences Stock Performance
Gilead Sciences stock traded up $0.06 during mid-day trading on Monday, reaching $89.94. 6,521,645 shares of the company traded hands, compared to its average volume of 6,113,990. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The firm's fifty day moving average is $91.94 and its two-hundred day moving average is $83.54. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market capitalization of $112.09 billion, a price-to-earnings ratio of 999.33, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. During the same period last year, the business posted $2.29 earnings per share. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.42%. The ex-dividend date was Friday, December 13th. Gilead Sciences's dividend payout ratio is currently 3,422.22%.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 8,500 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the transaction, the chief financial officer now directly owns 132,373 shares of the company's stock, valued at approximately $12,173,021.08. The trade was a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 453,734 shares of company stock valued at $41,902,086. 0.16% of the stock is owned by company insiders.
Analysts Set New Price Targets
A number of equities analysts have commented on GILD shares. Mizuho lifted their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, November 21st. Bank of America reiterated a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Robert W. Baird upped their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Citigroup started coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a "buy" rating and a $125.00 target price for the company. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $97.96.
Get Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
